Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 14/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125303 | 0.79 | GPR84 (0.69) | MEN1KMT2ATSHRGPR84SMN1; SMN2 | |
| SCHEMBL803563 | 0.78 | PKM (0.54) | TSHRGPR84SMN1; SMN2PKMMAPT | |
| SCHEMBL28318739 | 0.77 | GPR84 (0.80) | TSHRGPR84SMN1; SMN2 | |
| SCHEMBL15457569 | 0.76 | PKM (0.53) | MEN1KMT2ATSHRGPR84SMN1; SMN2 | |
| SCHEMBL18931726 | 0.76 | PKM (0.53) | MEN1KMT2ASMN1; SMN2PKMMAPT | |
| SCHEMBL5552693 | 0.76 | SCN9A (0.55) | MEN1KMT2APKMPOLB | |
| SCHEMBL1733432 | 0.76 | GPR84 (0.58) | MEN1KMT2ATSHRGPR84PKM | |
| SCHEMBL13125306 | 0.74 | TSHR (1.00) | MEN1KMT2ATSHRGPR84SMN1; SMN2 | |
| SCHEMBL25350548 | 0.73 | PKM (0.68) | KMT2ASMN1; SMN2PKMMAPTPOLB | |
| SCHEMBL17422233 | 0.73 | POLB (0.50) | MEN1KMT2ATSHRGPR84SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841847-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM RCV GMBH & CO. KG (AT) | 2025-01-02 | — | — | US | disclosed |
| EP-4441055-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-09 | — | — | EP | disclosed |
| US-12060367-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-08-13 | — | — | US | disclosed |
| US-20240174690-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| CN-220257206-U | 4-6-dihydroxy-2-methylthiopyrimidine hydrothermal recrystallization kettle | 江苏鸣翔化工有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
| WO-2023099624-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| EP-3481819-B1 | COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS | ACQUIST LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC | 2020-06-25 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | ACQUIST LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | ACQUIST LLC (US) | 2019-04-25 | — | — | US | disclosed |
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | MEN1 559/4885KMT2A 832/4885TSHR 1257/4885 |
| US-20250002504-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | MEN1 559/4885KMT2A 832/4885TSHR 1257/4885 |
| US-10688095-B2 | Compounds and their use for reducing uric acid levels | XDH, OAT, UGT2B7 | MEN1 2537/4885KMT2A 2533/4885TSHR 2010/4885 |
| US-20210236495-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | MEN1 3166/4885KMT2A 3100/4885TSHR 2953/4885 |
| US-20200268757-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | MEN1 3166/4885KMT2A 3100/4885TSHR 2953/4885 |
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | MEN1 1472/4885KMT2A 2565/4885TSHR 2976/4885 |
| US-20240174690-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | MEN1 559/4885KMT2A 832/4885TSHR 1257/4885 |
| US-20200197393-A9 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | MEN1 3166/4885KMT2A 3100/4885TSHR 2953/4885 |
| US-20190117654-A1 | Compounds and Their Use for Reducing Uric Acid Levels | XDH, OAT, URB2 | MEN1 3166/4885KMT2A 3100/4885TSHR 2953/4885 |
| US-12060367-B2 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer | KRAS, NRAS, TP53 | MEN1 559/4885KMT2A 832/4885TSHR 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.